Friday, March 24, 2017 8:26:56 PM
Phase 1 and 2a clinical trials of GOVX-B11: The GOVX-B11 vaccine has been tested at various doses and
regimens by the HVTN in trials involving approximately 500 participants. In these trials, the vaccine has
been extremely well tolerated. In terms of pain and tenderness at the site of inoculation, DNA
inoculations have been indistinguishable from placebo inoculations. Following MVA inoculations, about
70% of participants have transient mild pain, and 25% transient moderate pain at the site of injection.
Figures 8 and 9 depict the excellent response rates for antibody dependent cellular cytotoxicity (ADCC)
elicited by the GOVX-B11 vaccine. In Figure 8, ADCC is measured for gp120. Note the increase in the
response rate with the third MVA boost. The 64% response rate observed here is lower than the 70-90%
response rate observed in RV144. However, the GOVX-B11 elicited response was still scoring at 6
months post the peak vaccine response, whereas the response elicited in RV144 had declined to
undetectable levels by this time (Figure 8). Figure 9 shows an assay where responses score both gp120
and gp41 epitopes exposed during viral entry. Again, the response is highest after the third MVA boost.
The 85% response rate is also higher than the 64% response rate seen for gp120 alone.
Summary: GOVX-B11 is a VLP-expressing DNA/MVA vaccine that elicits a broad-based Ab and T cell
response capable of providing preclinical protection against a heterologous challenge. Based on the
partially successful RV144 trial, the Ab responses elicited by GOVX-B11 have strong features for reducing
the risk of infection. These features include excellent IgG3 to IgA ratios, outstanding durability, multiple
target specificities including the highly conserved immunodominant region of gp41 and excellent activity
in assays for antibody-dependent cellular cytotoxicity. Testing of this vaccine in a pivotal efficacy trial
provides a unique opportunity to identify a vaccine capable of ending the persistence of HIV in the
United States
We are going to wake up one morning trading multi dollars and are life's will be financially well off. And the company we invested in is going to shock the world with a HIV vaccine don't forget all the other pandemic and cancer Immunotherapy vaccines there working on this is a multi billion dollar company in the making.
http://www.voanews.com/a/partially-effective-hiv-vaccine-could-help-turn-corner-on-pandemic/3776689.html
https://www.geovax.com/clinical-pipeline.html
$GOVX
Recent GOVX News
- GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine • GlobeNewswire Inc. • 04/04/2024 04:30:00 PM
- GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress • GlobeNewswire Inc. • 03/28/2024 01:00:00 PM
- GeoVax to Present at the 36th Annual Roth Conference • GlobeNewswire Inc. • 03/12/2024 01:00:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 03/11/2024 08:13:14 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/11/2024 04:15:24 AM
- GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System • GlobeNewswire Inc. • 03/06/2024 02:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/01/2024 09:08:47 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 09:05:14 PM
- GeoVax Reports 2023 Year-End Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:41:26 PM
- GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 • GlobeNewswire Inc. • 02/22/2024 02:00:00 PM
- GeoVax to Present at the 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/19/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:01:35 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:25 PM
- GeoVax Announces Multiple Patent Issuances and Allowances • GlobeNewswire Inc. • 02/13/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:43:48 PM
- GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster • GlobeNewswire Inc. • 02/06/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 06:13:27 PM
- GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement • GlobeNewswire Inc. • 01/29/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:03:40 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/12/2024 09:00:38 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM